Advancing Care in Colorectal Cancer: Navigating Treatment After Progression

home / practice-pearls / advancing-care-in-colorectal-cancer-navigating-treatment-after-progression

Ryan Haumschild, PharmD, MS, MBA, CPEL; Patrick Boland, MD, and Ashley Finamore, PharmD, BCOP discuss how to optimize third-line treatment decisions in metastatic colorectal cancer by balancing efficacy data from trials like SUNLIGHT (which showed improved survival with trifluridine/tipiracil plus bevacizumab) with patient-specific factors including quality of life, tolerability profiles, pill burden considerations, and individualized shared decision-making approaches that prioritize what patients value most in their treatment journey.

3 experts are featured in this series.

EP. 1: Evolving Third-Line mCRC Treatment: Mechanisms, Efficacy, and Insights

Ryan Haumschild, PharmD, MS, MBA, CPEL ;Patrick Boland, MD ;Ashley Finamore, PharmD, BCOP
July 31st 2025

Panelists discuss how third-line metastatic colorectal cancer treatment has evolved from limited options like FOLFOX and FOLFIRI to multiple available agents including regorafenib, trifluridine/tipiracil, trifluridine/tipiracil plus bevacizumab, and fruquintinib, emphasizing the importance of comprehensive biomarker testing to identify rare fusions and actionable targets before selecting among these therapies, each with distinct mechanisms of action and tolerability profiles that require careful sequencing and adherence management to optimize clinical outcomes.

Watch